Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Status and phase

Terminated

Phase 2

Conditions

Colorectal Neoplasms

Treatments

Drug: Bevacizumab

Drug: Capecitabine

Drug: Oxaliplatin

Drug: Irinotecan

Study type

Interventional

Funder types

Other

NETWORK

Industry

Identifiers

NCT00314353

NSABP FC-BV-003

Details and patient eligibility

About

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.

Full description

Due to greater patient convenience and favorable toxicity profiles, clinical practice has seen an increased use of the combinations of capecitabine with oxaliplatin (CAPOX) and capecitabine with irinotecan (CAPIRI). Given the data documenting the improved efficacy for 5-FU based chemotherapy in combination with bevacizumab, it is important to investigate the potential advantages of adding this agent to regimens containing capecitabine.

Enrollment

7 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pathological diagnosis of colon or rectal cancer from either the colon or rectum or a metastatic site (beyond the colon or rectum)
Evidence of adequate organ function (such as liver, kidneys, etc.)

Exclusion criteria